<span>Labcorp receives emergency use authorization for first non-prescription at-home collection kit for combined COVID-19, flu and RSV detection</span>
May 18, 2022

Labcorp receives emergency use authorization for first non-prescription at-home collection kit for combined COVID-19, flu and RSV detection

BURLINGTON, N.C. --(BUSINESS WIRE)--May 18, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, today announced the receipt of of Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a combined at-home collection kit available that simultaneously detects COVID-19, influenza A/B and respiratory syncytial virus (RSV), a common but contagious respiratory virus often seen in children.
<span>Labcorp strengthens oncology leadership position with the addition of Personal Genome Diagnostics, a provider of comprehensive liquid biopsy and tissue-based genomic products and services</span>
December 23, 2021

Labcorp strengthens oncology leadership position with the addition of Personal Genome Diagnostics, a provider of comprehensive liquid biopsy and tissue-based genomic products and services

BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 23, 2021-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has entered into a definitive agreement to acquire Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products.
<span>Labcorp and ConcertAI optimize precision oncology research with real-world data and artificial intelligence</span>
December 1, 2021

Labcorp and ConcertAI optimize precision oncology research with real-world data and artificial intelligence

BURLINGTON, N.C. & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 1, 2021-- Labcorp (NYSE: LH), a leading global life sciences company, and ConcertAI, LLC (ConcertAI), a leader in enterprise artificial intelligence (AI) and real-world data (RWD) solutions for life science companies and health care providers, today announced a collaboration to optimize precision oncology research. The companies will work together to launch clinical studies in ways that minimize the burden on physician practices, drive faster patient recruitment, maximize patient retention and ensure equitable access to research as a care option.
April 30, 2021

OmniSeq receives New York state approval for OmniSeq INSIGHT genomic and immune profiling test

BUFFALO, N.Y., April 28, 2021 - OmniSeq®, an innovator in next generation sequencing in oncology, today announced the New York State Department of Health's Clinical Laboratory Evaluation Program has approved the OmniSeq INSIGHTSM  test. The test detects genomic variants, genomic signatures, and immune gene expression, providing physicians with clinically actionable evidence to inform therapeutic treatment decisions and identify potential clinical trial options for patients with late-stage solid tumor cancers.